Echocardiographic characterization of hypertrophic cardiomyopathy in Chinese patients with myosin-binding protein C3 mutations

Zhao,Bei; Wang,Shouli; Chen,Jinsong; Ji,Yali; Wang,Jing; Tian,Xiaoli; Zhi,Guang

doi:10.3892/etm.2017.4089

Echocardiographic characterization of hypertrophic cardiomyopathy in Chinese patients with myosin-binding protein C3 mutations

Authors:
- Bei Zhao
- Shouli Wang
- Jinsong Chen
- Yali Ji
- Jing Wang
- Xiaoli Tian
- Guang Zhi
View Affiliations

Affiliations: Department of Cardiology, The 306th Hospital of Chinese People's Liberation Army, Beijing 100101, P.R. China, Department of Cardiology, Xiamen University Affiliated to Dongnan Hospital, Zhangzhou, Fujian 363000, P.R. China, Department of Information, The 306th Hospital of Chinese People's Liberation Army, Beijing 100101, P.R. China, Department of Cardiology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Human Population Genetic Institute of Molecular Medicine, Peking University, Beijing 100871, P.R. China
Published online on: January 25, 2017 https://doi.org/10.3892/etm.2017.4089
Pages: 995-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant cardiac disease, affecting 1 in 500 people. Myosin‑binding protein C3 (MyBPC3) gene mutations are the most common genetic cause of HCM. However, the prevalence of the MyBPC3 gene mutation in Chinese patients with HCM, and their echocardiographic characteristics, remain unknown. In the present study, 48 Chinese patients with HCM were sequenced to identify the MyBPC3 gene and were characterized by their clinical features using 2‑dimensional echocardiography and real‑time 3‑dimensional echocardiography. Nine MyBPC3 mutations were identified in seven unrelated patients out of 48 cases, which accounts for a 15% prevalence of MyBPC3 mutations in Chinese patients with HCM. Family members of the seven patients were further tested and divided into the following two groups based on HCM phenotype and MyBPC3 mutations: Positive genotype with left ventricular (LV) hypertrophy (LVH) (G+/LVH+, n=18); and positive genotype without LVH (G+/LVH‑, n=23). These groups were compared with matched normal control subjects (n=30). G+/LVH+ patients showed significantly lower septal and lateral Tissue Doppler imaging (TDI)‑derived systolic, early and late diastolic mitral annular velocities compared with the controls. In addition, diastolic dyssynchrony index (DDI) was markedly higher in the G+/LVH+ subjects. However, only septal Ea was significantly lower in G+/LVH‑ subjects in comparison with controls, with no significant difference in lateral Sa, Ea and Aa, and DDI. In conclusion, the patients in the present study demonstrated a 15% prevalence of MyBPC3 gene mutations in the Chinese HCM population. MyBPC3 gene mutations may cause regional LV hypertrophic remodeling first and further proceed to global hypertrophic remodeling and myocardial diastolic dysfunction.

View Figures

View References

1	Elliott P and McKenna WJ: Hypertrophic cardiomyopathy. Lancet. 363:1881–1891. 2004. View Article : Google Scholar : PubMed/NCBI
2	Landstrom AP and Ackerman MJ: Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation. 122:2441–2449; discussion 2450. 2010. View Article : Google Scholar : PubMed/NCBI
3	Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE and Seidman JG: Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 326:1108–1114. 1992. View Article : Google Scholar : PubMed/NCBI
4	Maron BJ, Maron MS and Semsarian C: Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J Am Coll Cardiol. 60:705–715. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wang L, Seidman JG and Seidman CE: Narrative review: Harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med. 152:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
6	Flavigny J, Robert P, Camelin JC, Schwartz K, Carrier L and Berrebi-Bertrand I: Biomolecular interactions between human recombinant beta-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. Cardiovasc Res. 60:388–396. 2003. View Article : Google Scholar : PubMed/NCBI
7	Kimura A: Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J. 72:(Suppl A). A-38–A48. 2008. View Article : Google Scholar
8	Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG and Seidman CE: Homozygous mutation in cardiac troponin T: Implications for hypertrophic cardiomyopathy. Circulation. 102:1950–1955. 2000. View Article : Google Scholar : PubMed/NCBI
9	Richard P, Charron P, Leclercq C, Ledeuil C, Carrier L, Dubourg O, Desnos M, Bouhour JB, Schwartz K, Daubert JC, et al: Homozygotes for a R869G mutation in the beta-myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 32:1575–1583. 2000. View Article : Google Scholar : PubMed/NCBI
10	Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG and Seidman CE: Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 38:315–321. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H and Williams WG: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 28:1–83. 1985. View Article : Google Scholar : PubMed/NCBI
12	McKenna WJ, Spirito P, Desnos M, Dubourg O and Komajda M: Experience from clinical genetics in hypertrophic cardiomyopathy: Proposal for new diagnostic criteria in adult members of affected families. Heart. 77:130–132. 1997. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-tie quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P and Maron BJ: Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 342:1778–1785. 2000. View Article : Google Scholar : PubMed/NCBI
15	Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ and Wigle ED: Task Force on Clinical Expert Consensus Documents, American College of Cardiology; Committee for Practice Guidelines, European Society of Cardiology: American college of cardiology/European society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American college of cardiology foundation task force on clinical expert consensus documents and the European society of cardiology committee for practice guidelines. J Am Coll Cardiol. 42:1687–1713. 2003. View Article : Google Scholar : PubMed/NCBI
16	McKenna WJ, Spirito P, Desnos M, Dubourg O and Komajda M: Experience from clinical genetics in hypertrophic cardiomyopathy: Proposal for new diagnostic criteria in adult members of affected families. Heart. 77:130–132. 1997. View Article : Google Scholar : PubMed/NCBI
17	Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T and Verani MS: American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac Imaging committee of the council on clinical cardiology of the American Heart Association. Circulation. 105:539–542. 2002. View Article : Google Scholar : PubMed/NCBI
18	Elliott P and McKenna WJ: Hypertrophic cardiomyopathy. Lancet. 363:1881–1891. 2004. View Article : Google Scholar : PubMed/NCBI
19	Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ and Ackerman MJ: Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 80:463–469. 2005. View Article : Google Scholar : PubMed/NCBI
20	Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ and Ackerman MJ: Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 44:1903–1910. 2004. View Article : Google Scholar : PubMed/NCBI
21	Barefield D and Sadayappan S: Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol. 48:866–875. 2010. View Article : Google Scholar : PubMed/NCBI
22	Oakley CE, Chamoun J, Brown LJ and Hambly BD: Myosin binding protein-C: Enigmatic regulator of cardiac contraction. Int J Biochem Cell Biol. 39:2161–2166. 2007. View Article : Google Scholar : PubMed/NCBI
23	Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE and Seidman JG: A mouse model of familial hypertrophic cardiomyopathy. Science. 272:731–734. 1996. View Article : Google Scholar : PubMed/NCBI
24	Michele DE, Gomez CA, Hong KE, Westfall MV and Metzger JM: Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is trans-gene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ Res. 91:255–262. 2002. View Article : Google Scholar : PubMed/NCBI
25	Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, et al: Classification of the cardiomyopathies: A position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 29:270–276. 2008. View Article : Google Scholar : PubMed/NCBI
26	Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ and Ackerman MJ: Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 44:1903–1910. 2004. View Article : Google Scholar : PubMed/NCBI
27	Spirito P and Maron BJ: Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. 15:808–813. 1990. View Article : Google Scholar : PubMed/NCBI
28	Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quiñones MA, Roberts R and Marian AJ: Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 104:128–130. 2001. View Article : Google Scholar : PubMed/NCBI
29	Marsan NA, Tops LF, Nihoyannopoulos P, Holman ER and Bax JJ: Real-time three dimensional echocardiography: Current and future clinical applications. Heart. 95:1881–1890. 2009. View Article : Google Scholar : PubMed/NCBI
30	McKenna WJ, Stewart JT, Nihoyannopoulos P, McGinty F and Davies MJ: Hypertrophic cardiomyopathy without hypertrophy: Two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J. 63:287–290. 1990. View Article : Google Scholar : PubMed/NCBI